Report calls for evidence-based strategies to address Alzheimer's-related psychosis
Reports and Proceedings
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 20-Jun-2026 08:15 ET (20-Jun-2026 12:15 GMT/UTC)
“Alzheimer’s-Related Psychosis: Interdisciplinary Perspectives for Understanding and Responding to Delusions and Hallucinations” — the latest report in The Gerontological Society of America’s Insights & Implications in Gerontology series — underscores the clinical, emotional, and societal impact of psychosis in individuals living with Alzheimer’s disease and stresses the need for comprehensive, person-centered approaches to care.
Monash University researchers have found in laboratory experiments that a drug which delivers copper to the brain significantly reduces toxic Alzheimer’s proteins and improves long-term spatial memory.
A study published in Cell advances understanding of how drugs shape vital cellular structures known as biomolecular condensates, blob-like mechanisms that drive gene regulation processes and have been linked to Alzheimer's, ALS and cancer.
Smartphone- or tablet-based memory tests can capture cogntive decline more quickly than conventional testing. These findings come from a study by DZNE in collaboration with university hospitals in Germany, the University of Wisconsin–Madison in the US, and the start-up “neotiv”. In the researchers’ view, digital tests like these could help accelerate clinical trials for new dementia drugs, particularly regarding Alzheimer’s disease. Over the longer term, they also see potential for use in clinical routine. The results were published in the scientific journal “npj Digital Medicine” and are based on data from about 200 older adults.